When was Persephone Biosciences founded?

Persephone Biosciences was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Persephone Biosciences located?

Persephone Biosciences is headquartered in San Diego, United States.

Who is the current CEO of Persephone Biosciences?

Stephanie Culler of Persephone Biosciences.

How many employees does Persephone Biosciences have?

As of May 31, 2026, the latest employee count at Persephone Biosciences is 19.

Is Persephone Biosciences a funded company?

Persephone Biosciences is a funded company, having raised a total of $15.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 19, 2021.

When was the latest funding round of Persephone Biosciences?

Persephone Biosciences' latest funding was a $***** Seed round on Jul 19, 2022, with participation from 8 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.39B in funding in 2026 to date.

Where does Persephone Biosciences rank among its competitors?

Persephone Biosciences ranks 775th amongst 3290 active competitors, of which 1118 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Persephone Biosciences?

Persephone Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Persephone Biosciences - 2026 Company Profile, Team, Funding & Competitors

Persephone Biosciences is a seed company based in San Diego (United States), founded in 2017 by Stephanie Culler and Steve Van Dien. It operates as a Developer of AI platform and therapeutics to treat cancer. Persephone Biosciences has raised $15.3M in funding from Propel Bio Partners and First Bight Ventures. The company has 3290 active competitors, including 1118 funded and 776 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of AI platform and therapeutics to treat cancer. The company has developed a platform that uses artificial intelligence for population-scale patient data analytics and develops microbiome-based therapies to treat cancer. It has also developed CURE-19 platform for at-home COVID-19 clinical trials.

Website: persephonebiosciences.com
Social

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Seed

Total Funding

$15.3M in 2 rounds

Latest Funding Round

Seed, Jul 19, 2022, $*****

Investors

Propel Bio Partners & 12 more

Ranked

775^th among 3290 active competitors

Employee Count

19 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2982 more

View Persephone Biosciences' full profile

Persephone Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Persephone Biosciences Inc., CIN: 520-2765 , United States, Active		-	-	-

Persephone Biosciences has raised a total funding of $15.3M over 2 rounds. Its first funding round was on Feb 19, 2021. Its latest funding round was a Seed round on Jul 19, 2022 for $*****. 8 investors participated in its latest round. Persephone Biosciences has 13 institutional investors.

Here is the list of recent funding rounds of Persephone Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 19, 2022	8128619	Seed	2230323	2639286	7825542	8787650
Feb 19, 2021	8266649	Seed	5943052	8695474	1208646	1055013

Access funding benchmarks and valuations. Sign up today!

View details of Persephone Biosciences's funding rounds and investors

The founders of Persephone Biosciences are Stephanie Culler and Steve Van Dien.

Here are the details of Persephone Biosciences' key team members:

Stephanie Culler: Co-Founder & CEO of Persephone Biosciences and founder of 1 other company.
Steve Van Dien: Co-Founder of Persephone Biosciences and founder of 1 other company.

View details of Persephone Biosciences's Founder profiles and Board Members

Persephone Biosciences' employee count trend

Persephone Biosciences has 19 employees as of May 26. Here is Persephone Biosciences's employee count trend over the years:

Employee count trend for Persephone Biosciences

Uncover Persephone Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Persephone Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Persephone Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
775th	Persephone Biosciences 2017, San Diego (United States), Seed	Developer of AI platform and therapeutics to treat cancer	$15.3M	BioBrit, Susa Ventures & 11 others	45/100